Nearly a fifth of 11,000 people enrolled so far in a 30,000-volunteer U.S. trial testing a COVID-19 vaccine from Pfizer and German partner BioNTech <22UAy.F> are Black or Latino, groups among the hardest hit by the coronavirus virus pandemic, a top Pfizer executive said.
